The vaccine, named ‘Sputnik-5’ of Kovid-19, prepared by Russia’s Gamalaya National Institute of Epidemiology and Microorganism Research, has been found to be up to 92 percent effective. This was confirmed on the basis of data obtained from the most randomized placebo controlled Phase III trial in Russia. Earlier, American company Pfizer has also said that its vaccine has been found to be 90 percent effective.
A press release issued by Gamalaya and the Russian Direct Investment Fund (RDIF) stated that 40,000 Volunteers participated in the trial. These trials studied the effects of the vaccine on more than 16,000 volunteers who were vaccinated or placebo 21 days after the first injection.
The result of the statistical analysis of 20 cases of corona virus revealed that the Sputnik-5 vaccine is up to 92 percent effective after the second dose, the statement said. In September 2020, Dr. Reddy’s and RDIF entered into an agreement for the clinical trial of Sputnik-5 vaccine and its distribution in India. Under the agreement, RDIF will make one thousand crore doses of the vaccine available to Dr. Reddy’s.
Significantly, the leading pharmaceutical company Pfizer recently said that analysis of its vaccine has shown that it can be up to 90 percent effective in stopping Kovid-19. This indicates that the company’s trial of the vaccine is going well and it may file an application with the US regulator in this regard.